The frequency of any aPL, aCL, anti-β2GPI, LA test and non-criteria aPL combined in patients with different CVE outcomes
| CVE | aPL | aCL IgG/M | anti-β2GPI IgG/M | LA | Non-criteria aPL* | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Median* | N | Median* | N | Median* | N | Median* | N | Median† | |
| CVE (any) | 43 | 17.4 (2–56) | 39 | 18.2 (3–35) | 8 | 13.7 (5–28) | 30 | 15.4 (0–26) | 6 | 14.9 (7–27) |
| Stroke | 38 | 17.2 (2–56) | 37 | 22.0 (3–35) | 8 | 13.7 (5–28) | 28 | 15.8 (0–26) | 6 | 14.9 (7–27) |
| TIA | 13 | 11.7 (2–45) | 12 | 12.7 (0–23) | 0 | – | 10 | 13.42 (7–19) | 2 | 3 (2–4) |
*Median is given as median % (range).
†Antiprothrombin antibodies N=3; antiphosphatidylethanolamine antibodies N=1; antiphosphatidylinositol antibodies N=1; antiphosphatidylserine antibodies N=1; N: number of studies.
aCL, anticardiolipin antibodies; anti-β2GPI, anti-β2-glycoprotein I antibodies; aPL, antiphospholipid antibodies; CVE, cerebrovascular event; LA, lupus anticoagulant; TIA, transient ischaemic attack.